--- title: How RepTwin Closes the HCP Engagement Gap Behind Pharma's Clinical Trial Enrollment Problem description: Pharma's clinical trial enrollment failures start at the investigator site. RepTwin closes the HCP engagement gap that drives enrollment delays. image: https://blog.doceree.com/hubfs/reptwin-blog-banner-clinical-trial-enrollment-v6%20(1).png --- [Now Live Daily Command is live Explore](https://doceree.com/daily-command/launch) [![Doceree](https://doceree.com/images/doceree-logo.svg)](https://doceree.com/) [Agencies](https://doceree.com/agencies) [Publishers](https://doceree.com/publishers) [EHR](https://doceree.com/ehr) [Hospital & health system](https://doceree.com/health-system) [Schedule a demo](https://doceree.com/contact#form) Solutions [Agencies](https://doceree.com/) [Publishers](https://doceree.com/publishers) [EHR](https://doceree.com/ehr) [Hospital & health system](https://doceree.com/health-system) Channels [![ABM](https://doceree.com/images/logos%20for%20cards/abm.svg)](https://doceree.com/channels/abm) [![Programmatic](https://doceree.com/images/runs/channels/programmatic.svg)](https://doceree.com/channels/programmatic) [![POC](https://doceree.com/images/runs/channels/poc.svg)](https://doceree.com/channels/ehr) [![DOOH](https://doceree.com/images/runs/channels/dooh-cis.png)](https://doceree.com/channels/dooh-powered-by-clinical-intent-signals) [![Email](https://doceree.com/images/runs/channels/email.svg)](https://doceree.com/channels/email) [![SMS](https://doceree.com/images/runs/channels/sms.svg)](https://doceree.com/channels/sms) [![RepTwin](https://doceree.com/images/logos%20for%20cards/reptwin.svg)](https://doceree.com/channels/reptwin) Solutions [![Marketplace](https://doceree.com/images/logos%20for%20cards/marketplace.svg)](https://doceree.com/marketplace) [![Co-pay.com](https://doceree.com/images/logos%20for%20cards/copay.com.svg)](https://doceree.com/channels/co-pay) [![NEXT](https://doceree.com/images/logos%20for%20cards/next.svg)](https://doceree.com/channels/next) Insights [Blogs](https://blog.doceree.com/) [Events](https://blog.doceree.com/events) [Media](https://info.doceree.com/media) [White paper](https://info.doceree.com/white-papers) [Case Studies](https://info.doceree.com/case-studies) [Ai Health 25](https://doceree.com/ai-health-25) [Health Decode](https://doceree.com/health-decode) About [Our Story](https://doceree.com/our-story) [Our Technology](https://doceree.com/technology) [Careers](https://doceree.com/careers) [Contact us](https://doceree.com/contact) [Exchange Login](https://exchange.doceree.com/login) [Schedule a demo](https://doceree.com/contact#form) [Available on Daily command](https://doceree.com/daily-command) ![RepTwin](https://blog.doceree.com/hubfs/reptwin-blog-banner-clinical-trial-enrollment-v6%20(1).png) [Home](https://blog.doceree.com/) > [Reptwin](https://blog.doceree.com/tag/reptwin) Share [facebook-f icon](http://www.facebook.com/share.php?u=https://blog.doceree.com/reptwin-clinical-trial-enrollment-hcp-engagement) [linkedin-in icon](http://www.linkedin.com/shareArticle?mini=true&url=https://blog.doceree.com/reptwin-clinical-trial-enrollment-hcp-engagement) [twitter icon](https://twitter.com/intent/tweet?url=https://blog.doceree.com/reptwin-clinical-trial-enrollment-hcp-engagement) [pinterest-p icon](http://pinterest.com/pin/create/link/?url=https://blog.doceree.com/reptwin-clinical-trial-enrollment-hcp-engagement) [envelope icon](mailto:?body=https://blog.doceree.com/reptwin-clinical-trial-enrollment-hcp-engagement) # How RepTwin Closes the HCP Engagement Gap Behind Pharma's Clinical Trial Enrollment Problem July 2, 2026 Author: [Doceree](https://blog.doceree.com/author/doceree) 3 minute read Clinical trial enrollment failure is diagnosed as a patient recruitment problem. The data points somewhere else. The breakdown happens earlier, at the investigator site, where the HCPs responsible for identifying and enrolling eligible patients are managing full clinical schedules, understaffed research teams, and a sponsor relationship that responds too slowly when real questions arise. RepTwin addresses the HCP engagement gap that sits at the center of that failure. ## **Why clinical trial enrollment targets keep slipping** The Tufts Center for the Study of Drug Development published an updated quantification of delay costs in 2024, drawing on drug sales data across 645 drugs and biologics launched since 2000. The findings are specific: for an average drug or biologic, a single day of delay represents approximately $800,000 in unrealized prescription sales. Phase III trials carry an additional direct operational cost of $55,716 per day. The enrollment data that produces those delays is equally direct. A 2025 analysis by Clinical Leader reports that 80 to 85 percent of clinical trials fail to meet their initial enrollment projections. Nearly 30 percent of investigator sites enroll zero patients. These are not outliers. They describe the structural baseline for clinical development across therapeutic areas. And the structure that produces them is not patient supply. It is investigator-level HCP engagement  ## **Where the enrollment gap actually sits** The investigator site is where enrollment either happens or stalls. An investigator who takes on a protocol has committed, in theory, to recruiting eligible patients. In practice, they run a full clinical schedule, manage a research coordinator handling multiple concurrent studies, and absorb an administrative load that grows with every protocol amendment and site query. The engagement model most sponsors rely on, periodic CRA visits and scheduled check-in calls, doesn't match the pace at which enrollment decisions actually happen. An investigator who can't quickly resolve a patient eligibility question won't hold a clinic appointment to wait for a sponsor callback. The patient moves on. The site falls behind its enrollment target. That sequence repeats across sites until the trial timeline slips. The failure is an HCP engagement failure. Better patient outreach doesn't resolve it. The gap sits at the sponsor-to-investigator level, and closing it requires a different model of site-level engagement. ## **How RepTwin's HCP engagement platform addresses the enrollment gap** [RepTwin](https://reptwin.ai/)is first ever AI-powered virtual brand rep built for the pharma environment, designed to cover the communication gaps that scheduled CRA support leaves open. At the investigator site level, RepTwin provides on-demand responses to the questions that determine whether patient enrollment moves forward. An eligibility question before a 7am clinic session gets answered without a callback queue. A site coordinator who needs protocol clarification during a patient pre-screening gets a response drawn from approved sponsor materials, in real time. An investigator managing a high-volume practice gets a resource that reduces trial administrative friction without pulling time away from patient care. [RepTwin](https://reptwin.ai/) operates within the compliance requirements of a regulated research environment. All responses draw from MLR-reviewed, sponsor-approved content. Off-protocol queries are escalated to the appropriate human contact. Every interaction is logged with a full audit trail. The platform is HIPAA certified, GDPR compliant, and SOC2 certified. RepTwin also supports proactive outreach to investigators whose patient populations match a trial's enrollment criteria but who haven't yet been activated as sites. That gives sponsor teams the ability to build their site network before enrollment pressure begins rather than after timelines start slipping. ## **What consistent HCP engagement produces across a trial** The value of closing the site-level engagement gap compounds over the length of a study. A site that receives fast, accurate answers to eligibility questions enrolls patients more consistently. A site that gets timely protocol support handles amendments without enrollment interruptions. A network of sites reached through proactive outreach before a trial opens builds early momentum rather than losing the first months to activation delays. [RepTwin](https://reptwin.ai/) covers clinical trial site engagement as part of a broader platform that manages HCP interactions across the full commercial and medical affairs spectrum, including [medical information](https://reptwin.ai/solutions/medical-information/), [access and reimbursement](https://reptwin.ai/solutions/access-reimbursement/), and [pharmacovigilance](https://reptwin.ai/solutions/pharmacovigilance/). Sponsor teams get a single engagement infrastructure rather than a separate tool for each function. Clinical trial enrollment pressure doesn't ease by waiting. The engagement model that relieves it is available now. [Schedule a demo](https://reptwin.ai/contact/)to see how RepTwin supports clinical trial site engagement. ## **Frequently asked questions** | **Why do most clinical trials miss enrollment targets?** | | --- | | Most clinical trials miss enrollment targets because investigator sites lack responsive, real-time support during the clinical workflow. Eligibility questions go unanswered for days, protocol queries slow pre-screening, and the administrative burden on site coordinators reduces the time available for active patient identification. These are HCP engagement failures, not patient supply failures. | | **How does HCP engagement affect clinical trial enrollment outcomes?** | | Investigator HCP engagement determines whether a site actively recruits patients or passively waits for eligible candidates to appear. Sites that receive fast, accurate answers to protocol and eligibility questions maintain enrollment momentum. Sites that experience slow sponsor communication lose patients at pre-screening and fall behind target timelines. | | **How does RepTwin support clinical trial site teams?** | | [RepTwin](https://reptwin.ai/) provides on-demand, protocol-accurate responses to investigators and site coordinators across the channels they use during the clinical workflow. All responses draw from sponsor-approved materials. Off-protocol queries are escalated to a human contact. Every interaction is auditable, and the platform is HIPAA certified, GDPR compliant, and SOC2 certified. | [All posts](https://blog.doceree.com/all) ### Leave a Comment ![Doceree](https://doceree.com/images/doceree-logo.svg) Doceree is the connected infrastructure beneath healthcare commercialization, linking every clinical signal, decision, and channel to the outcomes that matter. [![HIPAA](https://doceree.com/images/compliance%20logos/hippa.png)](https://www.hhs.gov/hipaa/index.html) [![California Consumer Privacy Act (CCPA)](https://doceree.com/images/compliance%20logos/ccpa.png)](https://oag.ca.gov/privacy/ccpa) [![General Data Protection Regulation (GDPR)](https://doceree.com/images/compliance%20logos/gdpr.png)](https://gdpr.eu/) [![Trustworthy Accountability Group (TAG)](https://doceree.com/images/compliance%20logos/tag.png)](https://www.tagtoday.net/) [![IAB Transparency & Consent Framework](https://doceree.com/images/compliance%20logos/iab.png)](https://iabeurope.eu/transparency-consent-framework/) [![IAB Tech Lab](https://doceree.com/images/compliance%20logos/iab%20techlab.png)](https://iabtechlab.com/) [![Dun & Bradstreet Registered](https://doceree.com/images/compliance%20logos/dun.png)](https://profiles.dunsregistered.com/TPIN-BAS-004.aspx) ### Quick links - [Agencies](https://doceree.com/) - [Publishers](https://doceree.com/publishers) - [EHR](https://doceree.com/ehr) - [Hospital & Health System](https://doceree.com/health-system) - [Daily Command](https://doceree.com/daily-command) - [Our Story](https://doceree.com/our-story) - [Our Technology](https://doceree.com/technology) - [AI Health 25](https://doceree.com/ai-health-25) - [Health Decode](https://doceree.com/health-decode) - [co-pay.com](https://doceree.com/channels/co-pay) - [Marketplace](https://doceree.com/marketplace) - [Next](https://doceree.com/channels/next) ### Channels - [ABM](https://doceree.com/channels/abm) - [Programmatic](https://doceree.com/channels/programmatic) - [POC](https://doceree.com/channels/ehr) - [DOOH](https://doceree.com/channels/dooh-powered-by-clinical-intent-signals) - [Email](https://doceree.com/channels/email) - [SMS](https://doceree.com/channels/sms) - [RepTwin](https://doceree.com/channels/reptwin) ### Policies - [Privacy Policy](https://doceree.com/privacy-policy) - [Terms of Service - Advertiser](https://doceree.com/us-terms-of-service-advertiser) - [Program Policy Terms](https://doceree.com/us-program-policy-terms) - [Content Policy](https://doceree.com/us-content-policy) - [Media and Partner Resources](https://doceree.com/media-and-partner-resources) - [Patient Affordability Program Policy](https://doceree.com/us-patient-affordability-program-policy) - [Terms of Service - Marketplace](https://doceree.com/us-terms-of-service-marketplace) ### Address **US Headquarters** 150 John F Kennedy Pkwy, Suite 403, Short Hills, NJ 07078 **UK Office** MYO King's Cross, 50 York Way, London N1 9AB **India Office** Max Square, Floor 11, Plot No. C-3-C, Jaypee Wishtown, Noida, Sector 129, UP 201304 Follow us ```json { "@context" : "https://schema.org", "@type" : "BlogPosting", "author" : { "@type" : "Person", "name" : "Doceree", "url" : "https://blog.doceree.com/author/doceree" }, "dateModified" : "2026-07-02T06:55:11.190Z", "datePublished" : "2026-07-02T06:55:11.000Z", "headline" : "How RepTwin Closes the HCP Engagement Gap Behind Pharma's Clinical Trial Enrollment Problem", "image" : [ "https://blog.doceree.com/hubfs/reptwin-blog-banner-clinical-trial-enrollment-v6%20(1).png" ], "mainEntityOfPage" : { "@id" : "https://blog.doceree.com/reptwin-clinical-trial-enrollment-hcp-engagement", "@type" : "WebPage" }, "publisher" : { "@type" : "Organization", "logo" : { "@type" : "ImageObject", "url" : "https://blog.doceree.com/hubfs/doceree_logo-1.png" }, "name" : "Doceree Inc" } } ``` ```json { "@context" : "https://schema.org", "@type" : "Blog", "description" : "Explore Doceree’s Blog for expert insights on healthcare marketing, programmatic ads, and HCP engagement. Stay ahead with actionable strategies and industry trends.", "name" : "Doceree Blog", "publisher" : { "@type" : "Organization", "address" : [ { "@type" : "PostalAddress", "addressCountry" : "US", "addressLocality" : "Short Hills", "addressRegion" : "NJ", "postalCode" : "07078", "streetAddress" : "150 John F Kennedy Pkwy, Suite 420" }, { "@type" : "PostalAddress", "addressCountry" : "UK", "addressLocality" : "London", "postalCode" : "W1U 6AG", "streetAddress" : "83 Baker Street, Spaces" }, { "@type" : "PostalAddress", "addressCountry" : "IN", "addressLocality" : "Noida", "addressRegion" : "Uttar Pradesh", "postalCode" : "201304", "streetAddress" : "Max Square, Floor 11, Plot No. C3-C, Jaypee Wishtown, Noida-Greater Noida Expressway, Sector 129" } ], "contactPoint" : [ { "@type" : "ContactPoint", "areaServed" : "US", "availableLanguage" : [ "English" ], "contactType" : "Office Contact", "telephone" : "+1 973-262-5856" }, { "@type" : "ContactPoint", "areaServed" : "UK", "availableLanguage" : [ "English" ], "contactType" : "Office Contact", "telephone" : "+44 7480 917683" }, { "@type" : "ContactPoint", "areaServed" : "India", "availableLanguage" : [ "English", "Hindi" ], "contactType" : "Office Contact", "telephone" : "+91 96850 96363" } ], "founder" : { "@type" : "Person", "name" : "Harshit Jain MD", "sameAs" : [ "https://www.linkedin.com/in/harshitjain/", "https://www.harshitjain.co/", "https://twitter.com/doctorhj", "https://www.facebook.com/drharshitjain" ] }, "foundingDate" : "2020", "logo" : "https://doceree.com/wp-content/uploads/2022/06/doceree-pharmaceutical-marketing-company.svg", "name" : "Doceree", "url" : "https://doceree.com/" }, "sameAs" : [ "https://www.facebook.com/doceree/", "https://linkedin.com/company/doceree", "https://twitter.com/doceree", "https://info.doceree.com/", "https://doceree.com/", "https://en.wikipedia.org/wiki/Doceree", "https://yourstory.com/companies/doceree", "https://www.crunchbase.com/organization/doceree", "https://theorg.com/org/doceree", "https://tracxn.com/d/companies/doceree/__S6DPb1DNqPS5n6DyxOXny8RbvRH1fL7ZK6LvKOmzk_M" ], "url" : "https://blog.doceree.com/" } ``` ```json { "@context" : "https://schema.org", "@id" : "https://blog.doceree.com/doceree-dialogue-e15-ai-in-healthcare-pharma-marketing", "@type" : "PodcastEpisode", "actor" : [ { "@type" : "Person", "jobTitle" : "Chief Growth Officer", "name" : "Ritesh Patel", "worksFor" : { "@type" : "Organization", "name" : "Doceree" } }, { "@type" : "Person", "jobTitle" : "Senior Manager of Insights & Analysis", "name" : "Dan Lynch", "worksFor" : { "@type" : "Organization", "name" : "M3MI" } } ], "associatedMedia" : { "@type" : "VideoObject", "contentUrl" : "https://www.youtube.com/watch?v=9kD08EMsQ-g", "description" : "Dan Lynch of M3MI explores how AI in healthcare, audience intelligence, and continuous optimization are reshaping pharma marketing strategies in an increasingly complex digital ecosystem.", "embedUrl" : "https://www.youtube.com/embed/9kD08EMsQ-g?si=44Uts4w8p8JALQgo", "name" : "Doceree Dialogue - Ep 15 | What Pharma Data Gets Right—and What It Still Misses", "publisher" : { "@type" : "Organization", "logo" : { "@type" : "ImageObject", "url" : "https://blog.doceree.com/hubfs/doceree-white-logo-new.svg" }, "name" : "Doceree" }, "thumbnailUrl" : "https://img.youtube.com/vi/9kD08EMsQ-g/maxresdefault.jpg", "uploadDate" : "2026-02-21T00:00:00+00:00" }, "dateModified" : "2026-07-02", "datePublished" : "2026-07-02", "description" : "In this episode of Doceree Dialogue, Dan Lynch, Senior Manager of Insights & Analysis at M3MI, joins Doceree to discuss how pharma marketing is shifting from data-driven to AI-driven decision-making, the role of personalization, and the future of omnichannel healthcare engagement.", "image" : { "@type" : "ImageObject", "url" : "https://blog.doceree.com/hubfs/doceree-dialogue-episode-15-ai-in-healthcare-pharma-data-dan-lynch-1.jpg" }, "name" : "Doceree Dialogue Episode 15 | From Dashboards to Decisions: Rethinking Pharma Marketing in an AI-First World", "partOfSeries" : { "@id" : "https://doceree.com/doceree-dialogue", "@type" : "PodcastSeries", "name" : "Doceree Dialogue" }, "url" : "https://blog.doceree.com/doceree-dialogue-e15-ai-in-healthcare-pharma-marketing" } ``` ```json { "@context" : "http://schema.org", "@type" : "Article", "author" : { "@type" : "Person", "name" : [ "Doceree" ] }, "datePublished" : "2026-07-02T06:55:11+0000", "description" : "Pharma's clinical trial enrollment failures start at the investigator site. RepTwin closes the HCP engagement gap that drives enrollment delays.", "headline" : "How RepTwin Closes the HCP Engagement Gap Behind Pharma's Clinical Trial Enrollment Problem", "image" : "https://24898002.fs1.hubspotusercontent-eu1.net/hubfs/24898002/reptwin-blog-banner-clinical-trial-enrollment-v6%20%281%29.png", "publisher" : { "@type" : "Organization", "logo" : { "@type" : "ImageObject", "url" : "https://f.hubspotusercontent-eu1.net/hubfs/24898002/doceree_logo-1.png" }, "name" : "Doceree US" }, "url" : "https://blog.doceree.com/reptwin-clinical-trial-enrollment-hcp-engagement" } ```